Does the media prefer CRMD or TNXP?

In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Tonix Pharmaceuticals' score of 0.45 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tonix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NVCT or TNXP?

In the previous week, Nuvectis Pharma had 11 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 18 mentions for Nuvectis Pharma and 7 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.45 beat Nuvectis Pharma's score of 0.30 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Tonix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TNXP or ZVRA?

In the previous week, Zevra Therapeutics had 26 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 33 mentions for Zevra Therapeutics and 7 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.45 beat Zevra Therapeutics' score of 0.41 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MPLT or TNXP?

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Maplight Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 4 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Tonix Pharmaceuticals' score of 0.45 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Live Earnings Conference Call: Tonix Pharmaceuticals will host a live Q2 2026 earnings call on August 10, 2026 at 8:30AM ET. Get details.

Tonix Pharmaceuticals (TNXP) Competitors

$12.03 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$12.09 +0.06 (+0.52%)

As of 08:05 AM Eastern

Compare

TNXP vs. CRMD, NVCT, AVTE, ZVRA, and MPLT

Should you buy Tonix Pharmaceuticals stock or one of its competitors? MarketBeat compares Tonix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tonix Pharmaceuticals include CorMedix (CRMD), Nuvectis Pharma (NVCT), Aerovate Therapeutics (AVTE), Zevra Therapeutics (ZVRA), and Maplight Therapeutics (MPLT).

How does Tonix Pharmaceuticals compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

CorMedix presently has a consensus price target of $14.86, suggesting a potential upside of 99.69%. Tonix Pharmaceuticals has a consensus price target of $24.00, suggesting a potential upside of 99.50%. Given CorMedix's higher probable upside, equities analysts plainly believe CorMedix is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

CorMedix has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

34.2% of CorMedix shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CorMedix has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$400.05M	1.46	$163.05M	$2.13	3.49
Tonix Pharmaceuticals	$17.56M	10.92	-$124.02M	-$14.36	N/A

CorMedix has a net margin of 45.25% compared to Tonix Pharmaceuticals' net margin of -839.52%. CorMedix's return on equity of 45.57% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Tonix Pharmaceuticals' score of 0.45 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tonix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CorMedix beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Nuvectis Pharma has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

In the previous week, Nuvectis Pharma had 11 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 18 mentions for Nuvectis Pharma and 7 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.45 beat Nuvectis Pharma's score of 0.30 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvectis Pharma presently has a consensus price target of $35.00, suggesting a potential upside of 84.70%. Tonix Pharmaceuticals has a consensus price target of $24.00, suggesting a potential upside of 99.50%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Nuvectis Pharma has higher earnings, but lower revenue than Tonix Pharmaceuticals. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Tonix Pharmaceuticals	$17.56M	10.92	-$124.02M	-$14.36	N/A

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Tonix Pharmaceuticals beats Nuvectis Pharma on 9 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Aerovate Therapeutics?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Tonix Pharmaceuticals has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Aerovate Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$17.56M	10.92	-$124.02M	-$14.36	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

In the previous week, Tonix Pharmaceuticals had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.45 beat Aerovate Therapeutics' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Tonix Pharmaceuticals	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tonix Pharmaceuticals presently has a consensus price target of $24.00, suggesting a potential upside of 99.50%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Tonix Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Tonix Pharmaceuticals beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Tonix Pharmaceuticals currently has a consensus target price of $24.00, indicating a potential upside of 99.50%. Zevra Therapeutics has a consensus target price of $27.14, indicating a potential upside of 134.80%. Given Zevra Therapeutics' higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Zevra Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$17.56M	10.92	-$124.02M	-$14.36	N/A
Zevra Therapeutics	$106.47M	6.45	$83.23M	$0.92	12.57

In the previous week, Zevra Therapeutics had 26 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 33 mentions for Zevra Therapeutics and 7 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.45 beat Zevra Therapeutics' score of 0.41 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	8 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has a net margin of 42.82% compared to Tonix Pharmaceuticals' net margin of -839.52%. Zevra Therapeutics' return on equity of 54.54% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Zevra Therapeutics	42.82%	54.54%	34.15%

Tonix Pharmaceuticals has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zevra Therapeutics beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Maplight Therapeutics presently has a consensus target price of $34.42, suggesting a potential upside of 182.80%. Tonix Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 99.50%. Given Maplight Therapeutics' higher probable upside, equities analysts plainly believe Maplight Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.00
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Tonix Pharmaceuticals has higher revenue and earnings than Maplight Therapeutics. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Tonix Pharmaceuticals	$17.56M	10.92	-$124.02M	-$14.36	N/A

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Maplight Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 4 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Tonix Pharmaceuticals' score of 0.45 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maplight Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Maplight Therapeutics' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

Summary

Maplight Therapeutics beats Tonix Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Tonix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNXP vs. The Competition

Export

Metric	Tonix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$191.77M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.84	9.02	270.61	25.05
Price / Sales	10.92	1,287.31	657.91	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.63	17.69	11.26	6.43
Net Income	-$124.02M	-$13.25M	$3.45B	$348.10M
7 Day Performance	12.85%	5.04%	3.41%	2.66%
1 Month Performance	-3.99%	-2.10%	-0.71%	-0.85%
1 Year Performance	-74.12%	61.50%	77.43%	23.96%

Tonix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNXP Tonix Pharmaceuticals	3.889 of 5 stars	$12.03 flat	$24.00 +99.5%	-74.1%	$191.77M	$17.56M	N/A	50	Gap Down
CRMD CorMedix	2.5529 of 5 stars	$7.50 +0.1%	$14.86 +98.1%	-28.0%	$589.08M	$311.71M	3.53	30	Positive News Upcoming Earnings
NVCT Nuvectis Pharma	3.9462 of 5 stars	$21.94 -3.6%	$35.00 +59.5%	+215.8%	$582.73M	N/A	N/A	8	Earnings Report
AVTE Aerovate Therapeutics	N/A	$20.00 +3.4%	N/A	+193.2%	$579.70M	N/A	N/A	20	Gap Up High Trading Volume
ZVRA Zevra Therapeutics	4.3292 of 5 stars	$9.66 +0.2%	$26.86 +178.2%	-3.8%	$569.57M	$122.29M	4.84	20	News Coverage Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNXP) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. CRMD, NVCT, AVTE, ZVRA, and MPLT

How does Tonix Pharmaceuticals compare to CorMedix?

Summary

How does Tonix Pharmaceuticals compare to Nuvectis Pharma?

Summary

How does Tonix Pharmaceuticals compare to Aerovate Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. CRMD, NVCT, AVTE, ZVRA, and MPLT

How does Tonix Pharmaceuticals compare to CorMedix?

Do analysts prefer CRMD or TNXP?

Which has more volatility & risk, CRMD or TNXP?

Do institutionals and insiders hold more shares of CRMD or TNXP?

Which has better earnings & valuation, CRMD or TNXP?

Is CRMD or TNXP more profitable?

Does the media prefer CRMD or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Nuvectis Pharma?

Which has more risk & volatility, NVCT or TNXP?

Is NVCT or TNXP more profitable?

Does the media favor NVCT or TNXP?

Do analysts prefer NVCT or TNXP?

Which has preferable valuation and earnings, NVCT or TNXP?

Do insiders & institutionals believe in NVCT or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Aerovate Therapeutics?

Which has more risk and volatility, TNXP or AVTE?

Which has higher valuation and earnings, TNXP or AVTE?

Does the media prefer TNXP or AVTE?

Is TNXP or AVTE more profitable?

Do insiders and institutionals hold more shares of TNXP or AVTE?

Do analysts rate TNXP or AVTE?

Summary

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Do analysts rate TNXP or ZVRA?

Which has stronger valuation and earnings, TNXP or ZVRA?

Does the media prefer TNXP or ZVRA?

Is TNXP or ZVRA more profitable?

Which has more risk & volatility, TNXP or ZVRA?

Do insiders & institutionals believe in TNXP or ZVRA?

Summary

How does Tonix Pharmaceuticals compare to Maplight Therapeutics?

Do institutionals & insiders hold more shares of MPLT or TNXP?

Do analysts recommend MPLT or TNXP?

Which has preferable valuation & earnings, MPLT or TNXP?

Does the media refer more to MPLT or TNXP?

Is MPLT or TNXP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools